

Branched Chain Amino and Keto Acids in Health and Disease

Editors:

**S. A. Adibi, W. Fekl,
U. Langenbeck, P. Schauder**

International Symposium on Branched Chain Amino and Keto Acids
in Health and Disease, Göttingen, October 21-23, 1983

Branched Chain Amino and Keto Acids in Health and Disease

Editors

S. A. Adibi, Pittsburgh; *W. Fekl*, Erlangen;
U. Langenbeck, Göttingen; *P. Schauder*, Göttingen

144 figures and 194 tables, 1984



S. Karger · Basel · München · Paris · London · New York · Tokyo · Sydney

Editors addresses

Siamak A. Adibi
Clinical Nutrition Center
Montefiore Hospital
University of Pittsburgh
School of Medicine
Pittsburgh, Pennsylvania, USA

Werner Fekl
Research Institute of
Experimental Nutrition Erlangen
Erlangen, FRG

Ulrich Langenbeck
Institute of Human Genetics
University of Göttingen
Göttingen, FRG

Peter Schauder
Department of Medicine
Division of Gastroenterology
and Metabolism
University of Göttingen
Göttingen, FRG

National Library of Medicine, Cataloging in Publication

International Symposium on Branched Chain Amino and Keto Acids in Health and Disease
(1983: Göttingen, Germany)

Branched Chain Amino and Keto Acids in Health and Disease /

International Symposium on Branched Chain Amino and Keto Acids in Health and Disease,
Göttingen, October 21–23, 1983;

volume editors, S. A. Adibi . . . [et al.].

– Basel; New York: Karger, 1984. –

1. Amino Acids, Branched-Chain–metabolism–congresses

2. Amino Acids, Branched-Chain–therapeutic use–congresses

3. Keto Acids–metabolism–congresses

4. Keto Acids–therapeutic use–congresses

ISBN 3-8055-3996-7

QU 60 I598b 1983

All rights reserved

No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.

© Copyright 1984 by S. Karger AG, P.O. Box, CH-4009 Basel (Switzerland)
Printed in Germany by Stock & Körber GmbH, D-8750 Aschaffenburg
ISBN 3-8055-3996-7

Preface

Within the past few years there has been a large expansion of knowledge regarding the regulation of metabolism of branched-chain amino acids, and the effects of these amino acids and their metabolites on a range of metabolic reactions in various tissues of the body. This knowledge has already been used by clinical investigators to explain biochemical or physiological mechanisms of altered metabolism in common diseases, and to advocate the use of branched-chain amino acids and/or their ketoacid derivatives for therapeutic purposes. The first objective of this book is to bring together current reviews of these advances by basic and clinical scientists who have been the eminent leaders in this field. The editors hope that this book will be useful to the growing world-wide interest in metabolism and medical applications of branched-chain amino acids.

With any emerging new field there is always controversy and differing viewpoints. The field of branched-chain amino acids is no exception to this rule. The second objective of this book is to allow these controversies to be brought together to stimulate further research toward their resolutions.

While there has already been substantial progress in the metabolism of branched-chain amino acids and their involvement in metabolic reactions, much remains to be explored. The third objective of this book is to further stimulate basic and clinical research in this field.

Finally, under the auspices of the University of Göttingen School of Medicine and the Research Institute of Experimental Nutrition of Erlangen, an international symposium was held last October at the

Max-Planck Institute for Biophysical Chemistry in Göttingen. A select group of basic scientists and clinical investigators from different countries were invited to share observations and exchange ideas regarding their work on branched-chain amino acids in the intimate environment of this ancient and historic German city. The material covered in this book is largely, but not entirely, derived from the presentations made at this symposium.

S. A. Adibi
W. Fekl
U. Langenbeck
P. Schauder

Acknowledgment

The editors gratefully acknowledge the sponsorship of the symposium by the *German Diabetes Association*, the *Jacques Pfrimmer Foundation*, and the *B. Braun Foundation*.

The staff and the members of the Research Institute of Experimental Nutrition, Erlangen, in particular Dr. *Maria Brandl*, *Elke Becher* and *Irene Rotter*, were greatly helpful both in organizing the meeting and in preparing the book.

We thank the medical and scientific publishers of the *S. Karger GmbH* for their interest and cooperation in publishing this book.

S. A. Adibi
W. Fekl
U. Langenbeck
P. Schauder

Contributors

- Siamak A. Adibi*, Clinical Nutrition Center, Montefiore Hospital, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA
- Naji N. Abumrad*, Departments of Medicine and Surgery, Vanderbilt University School of Medicine, Nashville, Tennessee, USA
- Anders Alvestrand*, Department of Renal Medicine, Karolinska Institute, Huddinge, Sweden
- Colin E. Atterbury*, Department of Internal Medicine, Yale University School of Medicine, Veterans Administration Medical Center, West Haven, Connecticut, USA
- Michael Berger*, Medizinische Klinik, Universität Düsseldorf, BRD
- Jonas Bergström*, Department of Renal Medicine, Karolinska Institute, Huddinge, Sweden
- Eva Berto*, Second Division of Gastroenterology, Third Department of Internal Medicine, University of Rome „La Sapienza”, Rome, Italy
- Dennis M. Bier*, Departments of Medicine and Pediatrics, Washington University School of Medicine, St. Louis, Missouri, USA
- Jurjen de Boer*, Department of Biochemistry, University of Limburg, Maastricht, Netherlands
- Lubov Blinder*, Department of Physiology, University of Massachusetts Medical School, Worcester, USA
- Karl Brand*, Institut für Physiologische Chemie, Universität Erlangen-Nürnberg, BRD
- Carlo Cangiano*, Third Department of Internal Medicine, University of Rome „La Sapienza”, Rome, Italy
- Antonia Cascino*, Third Department of Internal Medicine, University of Rome „La Sapienza”, Rome, Italy
- Livio Capocaccia*, Second Division of Gastroenterology, Department of Medicine, University of Rome „La Sapienza”, Rome, Italy
- Eugenio Cersosimo*, Departments of Medicine and Surgery, Vanderbilt University School of Medicine, Nashville Tennessee, USA
- Cyril Chantler*, Department of Pediatrics, Evelina Children's Hospital, Guy's Hospital and Medical School, University of London, U. K.
- Balvin H. L. Chua*, Department of Physiology, The Milton S. Hershey Medical Center, The Pennsylvania State University College of Medicine, Hershey, Pennsylvania, USA
- Kathleen E. Coll*, Department of Biochemistry and Biophysics, University of Pennsylvania School of Medicine, Philadelphia, USA

- Harold O. Conn*, Department of Internal Medicine, Yale University School of Medicine, Veterans Administration Medical Center, West Haven, Connecticut, USA
- Barbara O. Corkey*, Department of Biochemistry and Biophysics, University of Pennsylvania, School of Medicine, Philadelphia, Pennsylvania, USA
- R. Neil Dalton*, Evelina Children's Hospital, Guy's Hospital and Medical School, University of London, U. K.
- Anders Dejgaard*, Hvidoere Hospital, Klampenborg, Denmark
- Eick-Hartwig Egberts*, Medizinische Universitätsklinik, Tübingen, BRD
- Ljusk S. Eriksson*, Departments of Medicine and Clinical Physiology, Huddinge University Hospital, Stockholm, Sweden
- Peter Ferenci*, I. Universitätsklinik für Gastroenterologie und Hepatologie, Wien, Austria
- Peter Frick*, Department of Physiology, University of Massachusetts Medical School, Worcester, USA
- Peter Fürst*, Institut für Biologische Chemie und Ernährungswissenschaft, Universität Hohenheim, Stuttgart, BRD
- H. Maurice Goodman*, Department of Physiology, University of Massachusetts Medical School, Worcester, USA
- Norman D. Grace*, Tufts University School of Medicine, The Faulkner Hospital, Jamaica Plain, Massachusetts, USA
- Norbert Gretz*, Nephrologische Klinik, Klinikum Mannheim, Universität Heidelberg, BRD
- Alfred Harper*, Departments of Nutritional Science and Biochemistry, University of Wisconsin, Madison, USA
- Sunna Hauschildt*, Institut für Physiologische Chemie, Universität Erlangen-Nürnberg, BRD
- George Haycock*, Evelina Children's Hospital, Guy's Hospital and Medical School, University of London, U. K.
- Hans V. Henning*, Medizinische Universitätsklinik, Abteilung Nephrologie, Universität Göttingen, BRD
- Douglas Horst*, Harvard Medical School, Lemuel Shattuck Hospital, Jamaica Plain, Massachusetts, USA
- Anthony L. Imbembo*, Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
- Hans-Georg Joost*, Institut für Pharmakologie und Toxikologie, Universität Göttingen, BRD
- Evans A. Jones*, Liver Diseases Section, National Institutes of Health, Bethesda, Maryland, USA
- Robert W. A. Jones*, Evelina Children's Hospital, Guy's Hospital and Medical School, University of London, U. K.
- Ulrich Keller*, Abteilung für Endokrinologie und Stoffwechsel, Universität Basel, Schweiz
- William W. Lacy*, Departments of Medicine and Surgery, Vanderbilt Medical School, Nashville, Tennessee, USA
- Ulrich Langenbeck*, Institut für Humangenetik, Universität Göttingen, BRD
- David Law*, Department of Medicine, University of New Mexico School of Medicine, Albuquerque, USA
- Sigurd Lenzen*, Institut für Pharmakologie und Toxikologie, Universität Göttingen, BRD
- Jürgen Lüthje*, Institut für Physiologische Chemie, Universität Erlangen-Nürnberg, BRD

- Timothy J. Maher*, Department of Pharmacology, Massachusetts College of Pharmacy and Allied Health Sciences, Boston, Massachusetts, USA
- Willy J. Malaisse*, Laboratory of Experimental Medicine, Brussels Free University, Brussels, Belgium
- Angeles Martin-Requero*, Centro de Investigaciones Biologicas, Instituto Gregorio Marañon, Madrid, Spain
- Manuela Merli*, Second Division of Gastroenterology, Third Department of Internal Medicine, University of Rome „La Sapienza”, Rome, Italy
- Pietro Miazzi*, Second Division of Gastroenterology, Third Department of Internal Medicine, University of Rome „La Sapienza”, Rome, Italy
- Connie Moreadith*, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
- Howard E. Morgan*, Department of Physiology, The Milton S. Hershey Medical Center, The Pennsylvania State University College of Medicine, Hershey, Pennsylvania, USA
- Elizabeth D. Moyer*, Departments of Pharmacology and Experimental Therapeutics and Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
- Santiago Muñoz*, Departments of Pharmacology and Experimental Therapeutics and Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
- Bernhard Neumann*, Institut für Physiologische Chemie, Universität Erlangen-Nürnberg, BRD
- Uwe Panten*, Institut für Pharmakologie und Toxikologie, Universität Göttingen, BRD
- Harbajan S. Paul*, Clinical Nutrition Center, Montefiore Hospital, Departments of Medicine and Biochemistry, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA
- Steven C. Pappas*, Liver Diseases Section, National Institutes of Health, Bethesda, Maryland, USA
- Peter Richards*, St. Mary's Hospital Medical School, London, U. K.
- Peter Riederer*, Ludwig Boltzmann Institut für Klinische Neurobiologie, Krankenhaus Lainz, Wien, Austria
- Susan Rigden*, Evelina Children's Hospital, Guy's Hospital and Medical School, University of London, U. K.
- Vittorio Riggio*, Second Division of Gastroenterology, Third Department of Internal Medicine, University of Rome „La Sapienza”, Rome, Italy
- Vittorio Rinaldi*, Second Division of Gastroenterology, Third Department of Internal Medicine, University of Rome „La Sapienza”, Rome, Italy
- Neil B. Rosenshein*, Department of Gynecology and Obstetrics, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
- Filippo Rossi-Fanelli*, Third Division of Internal Medicine, University of Rome „La Sapienza”, Rome, Italy
- Daria Sacchini*, Division of Infectious Diseases, University of Parma, Parma, Italy
- Daniel G. Sapir*, Departments of Pharmacology and Experimental Therapeutics and Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
- Peter Schauder*, Medizinische Universitätsklinik, Abteilung Gastroenterologie und Stoffwechselerkrankungen, Universität Göttingen, BRD
- Steven Schenker*, Department of Medicine, University of Texas Health Science Center, San Antonio, Texas, USA
- Eugene R. Schiff*, Department of Medicine, University of Miami School of Medicine, Florida, USA

Hans Schomerus, Medizinische Universitätsklinik Tübingen, BRD

Peter B. Soeters, Department of Surgery, State University of Limburg, Maastricht, Netherlands

Peter M. Stewart, Departments of Pharmacology and Experimental Therapeutics and Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA

Manfred Strauch, Nephrologische Klinik, Klinikum Mannheim Universität Heidelberg, BRD

Kay Tanaka, Department of Human Genetics, Yale University School of Medicine, New Haven, Connecticut, USA

Mark E. Tischler, Department of Biochemistry, University of Arizona, Tucson, USA

Richard S. Trompeter, Evelina Children's Hospital, Guy's Hospital and Medical School, University of London, U. K.

Hendrik Vilstrup, Department of Medicine, Division of Hepatology, Rigshospitalet, Copenhagen, Denmark

Alfredo L. Viteri, The Scott and White Clinic, Temple, Texas, USA

John Wahren, Departments of Medicine and Clinical Physiology, Huddinge University Hospital, Stockholm, Sweden

Elizabeth Walajtys-Rode, Institute of Internal Medicine, Warsaw Medical School, Clinic of Pneumonology, Poland

Mackenzie Walser, Departments of Pharmacology and Experimental Therapeutics and Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA

Udo Wendel, Universitäts-Kinderklinik, Universität Düsseldorf, BRD

John R. Williamson, Department of Biochemistry and Biophysics, University of Pennsylvania School of Medicine, Philadelphia, USA

Vernon R. Young, Departments of Nutrition and Food Science, Massachusetts Institute of Technology, Cambridge, USA

Siegfried Zielmann, Institut für Pharmakologie und Toxikologie, Universität Göttingen, BRD

Contents

Preface	V
Acknowledgment	VII
Contributors	XI

<i>Siamak A. Adibi</i> : Nutritional, Physiological and Clinical Significance of Branched Chain Amino Acids	1
--	---

Biochemistry

<i>Howard E. Morgan and Balvin H. L. Chua</i> : Leucine as a Regulator of Protein Synthesis and Degradation in Heart Muscle	15
<i>H. Maurice Goodman, Lubov Blinder and G. Peter Frick</i> : Interaction of Branched Chain Amino Acids with Lipid Metabolism in Adipose Tissue	22
<i>John R. Williamson, Barbara E. Corkey, Angeles Martin-Requero, Elisabeth Wa- lajtyś-Rode and Kathleen E. Coll</i> : α -Ketoisovalerate Metabolism in Liver and Interactions with Other Metabolic Pathways	41
<i>Alfred E. Harper</i> : Interrelationships among the Branched Chain Amino Acids . .	81
<i>Karl Brand, Sunna Hauschildt and Jürgen Lütjhe</i> : Effect of Diets on the Activity of Enzymes Involved in Branched Chain α -Keto Acid Metabolism	100
<i>Sunna Hauschildt, Bernhard Neumann and Karl Brand</i> : Regulation of Hepatic Branched Chain α -Keto Acid Dehydrogenase	112

Physiology and Pathophysiology

<i>Willy J. Malaisse</i> : Branched Chain Amino and Keto Acids as Regulators of In- sulin and Glucagon Release	119
<i>Uwe Panten, Siegfried Zielmann, Hans-Georg Joost and Sigurd Lenzen</i> : Branched Chain Amino and Keto Acids — Tools for the Investigation of Fuel Rec- ognition Mechanism in Pancreatic B-Cells	134
<i>Dennis M. Bier and Vernon R. Young</i> : Whole Body Protein Turnover: Is Leucine a Representative Tracer?	147

<i>Naji N. Abumrad, Eugenio Cersosimo and William W. Lacy: Physiologic Role of Branched Chain Amino and Keto Acids In Vivo</i>	162
<i>Harbhajan S. Paul and Siamak A. Adibi: Regulation of Branched Chain Amino Acid Catabolism</i>	182
<i>Ulrich Keller: Endocrine Control of Branched Chain Amino Acids in Man</i>	220
<i>Peter Schauder: Effect of Starvation, Dietary Protein, and Pancreatic Hormones on Branched Chain Keto Acid Blood Levels in Man</i>	228
<i>Timothy J. Maher: Plasma Branched Chain Amino Acids as Regulators of Brain Neurotransmitters</i>	242
<i>Michael Berger: Blood Branched Chain Amino Acid Levels in Patients with Diabetes, Obesity, and Endocrinal Tumours of the Pancreas</i>	260
<i>Peter Fürst: Intracellular and Plasma Branched Chain Amino Acid Interrelationship with Special Reference to Human Muscle Tissue</i>	268

Diseases

Genetic Disorders

<i>Kay Tanaka: Isovaleric Acidemia: Recent Progress in Biochemistry, Genetics, and Clinical Aspects</i>	279
<i>Ulrich Langenbeck: Pathobiochemical and Pathophysiologic Analysis of the MSUD Phenotype</i>	315
<i>Udo Wendel: Acute and Long-Term Treatment of Children with Maple Syrup Urine Disease</i>	335

Protein Wasting

<i>Daniel G. Sapir, Peter M. Stewart, Mackenzie Walser, Connie Moreadith, Elizabeth D. Moyer, Anthony L. Imbembo, Neil B. Rosenshein and Santiago Muñoz: Effects of Ketoleucine and of Leucine on Nitrogen Metabolism in Post-Operative Patients</i>	348
<i>Mark E. Tischler: Metabolic Response of Muscle to Trauma</i>	361

Kidney Diseases

<i>Peter Richards: Milestones in the Dietary Treatment of Chronic Renal Failure</i>	384
<i>Jonas Bergström and Anders Alvestrand: Therapy with Branched Chain Amino and Keto Acids in Chronic Uremia — A Review of the Literature</i>	391
<i>Neil Dalton, Robert W. A. Jones, Susan Rigden, Richard S. Trompeter, George Haycock and Cyril Chantler: The Use of Calcium Salts of Keto Acids for the Treatment of Uremia in Children</i>	423
<i>Norbert Gretz and Manfred Strauch: Therapeutic Effects of Branched Chain Amino and Keto Acids in Uremia. Methodologic Aspects in Planning Clinical Studies</i>	433
<i>Hans V. Henning: Metabolism of Branched Chain Keto and Amino Acids in Uraemia</i>	449

Liver Diseases

<i>Livio Capocaccia, Eva Berto, Carlo Cangiano, Antonia Cascino, Manuela Merli, Pietro Miazzo, Oliviero Riggio, Vittorio Rinaldi, Daria Sacchini and Filippo Rossi-Fanelli: The Pros and the Cons of the Amino Acid Neurotransmitter Hypothesis</i>	460
<i>Peter Ferenci, Peter Riederer, Steven C. Pappas and Evans A. Jones: Effects of Branched Chain Amino Acids on Ammonia Induced Changes in Neurotransmission</i>	472
<i>Peter B. Soeters and Jurjen de Boer: Why Are Plasma Branched Chain Amino Acid Levels Diminished in Patients with Liver Cirrhosis?</i>	483
<i>Hendrik Vilstrup and Anders Dejgaard: Treatment of Hepatic Encephalopathy with Branched Chain Amino Acid Enriched Solutions. A Review of Randomized Controlled Trials</i>	497
<i>Harold O. Conn, Douglas Horst, Norman D. Grace, Eugene R. Schiff, Steven Schenker, Alfredo L. Viteri, David Law and Colin E. Atterbury: A Randomized, Controlled Comparison of Dietary Protein with an Oral, Branched Chain Enriched Amino Acid Supplement in Portal-Systemic Encephalopathy</i>	505
<i>Eick-Hartwig Egberts and Hans Schomerus: Effect of Oral Treatment with Branched Chain Amino Acids on Portosystemic Encephalopathy</i>	524
<i>Ljusk S. Eriksson and John Wahren: How Effective Are Branched Chain Amino Acids in the Treatment of Patients with Liver Cirrhosis?</i>	540
<i>Peter Schauder: Pharmacokinetic Characteristics of Orally Administered Branched Chain α-Keto Acids in Patients with Liver Cirrhosis</i>	553
Subject Index	567

Nutritional, Physiological and Clinical Significance of Branched Chain Amino Acids

S. A. Adibi

Clinical Nutrition Center, Montefiore Hospital and the University of Pittsburgh
School of Medicine, Pittsburgh, Pennsylvania (USA)

It has taken more than a century for branched-chain amino acids to come of age in the world of biological and clinical science. These amino acids were discovered in the 19th century [1]. Leucine was obtained in impure form from cheese in 1819 by *Proust*, and in 1820 it was purified by *Braconnot*, who named it after the Greek word "Leukos", meaning white. Isoleucine was discovered and named by *Ehrlich* in 1904. Valine was discovered by *von Group-Besanez* in 1856. However, *Fischer*, in 1906, established its structure and its name.

The nutritional importance of branched-chain amino acids became established about the middle of this century by the results of studies of *Rose and co-workers* [1]. These studies showed that nitrogen balance in adults could not be maintained if any of the branched-chain amino acids was omitted from the diet. *Albanese* showed that the growth of human infants would be impaired if the diet was deficient in any of the branched-chain amino acids [1]. These studies led to the designation of branched-chain amino acids as essential amino acids, and to the formulation of daily requirements. These requirements, which form 46% of the daily need for essential amino acids, are currently used in designing chemically-defined diets for patients.

In 1954, *Menkes et al.* [2] discovered Maple Syrup Urine disease, a genetic disorder of impaired oxidative decarboxylation of branched-chain keto acids, which results in large concentrations of branched-chain amino and their keto acids in plasma. The disease is

characterized by mental and growth retardation and frequent bouts of metabolic and neurologic crises. It is rare for patients to survive past the second year. The discovery of genetic disorders of branched-chain amino acid oxidation promoted an interest in elucidating the pathways of oxidation of these amino acids. During the 1950's this problem was studied extensively. The results showed that branched-chain amino acids are first transaminated to their respective keto acids, and then through a series of oxidative reactions, these ketoacids are decarboxylated to acetoacetic acid and acetyl-CoA in the case of leucine, to propionyl-CoA and acetyl-CoA in the case of isoleucine, and to succinyl-CoA in the case of valine.

My own interest in branched-chain amino acids began in the mid-1960's when I was investigating the effect of diet on the plasma aminogram of normal human volunteers [3]. I found that among the amino acids, starvation uniquely increased the concentrations of all three branched-chain amino acids in plasma (fig. 1). Increases were evident within a day, reached a maximum by the second day, and persisted for seven to eight days. Resumption of a regular diet during the first week of starvation [4] or prolongation of starvation to two weeks [3] lowered the concentration of branched-chain amino acids to basal levels. In contrast to starvation, feeding healthy human volunteers a diet devoid of protein, but adequate in caloric content, lowered the plasma concentrations of branched-chain amino acids to below basal levels within one day (fig. 1). This reduction was more pronounced for valine than for leucine and isoleucine.

Reintroduction of protein into diet promptly returned the depressed levels of branched-chain amino acids to basal levels (fig. 1). These alterations in plasma concentration suggested that metabolism of branched-chain amino acids is under dietary control. In view of the absence of any knowledge of regulation of branched-chain amino acid metabolism by diet, it seemed that research in this area might yield useful information. Therefore, I began a series of experiments on various aspects of branched-chain amino acid metabolism, which have continued to the present day. As reviewed elsewhere [5], it is now clear that the increase in plasma branched-chain amino acid concentrations during brief starvation reflects the loss of body protein and the decrease in plasma branched-chain amino acid concentrations during protein deprivation reflects the conservation of body protein.

Since the early 1970's there has been growing interest in the studies of branched-chain amino acid metabolism [6]. The results of a number of studies have suggested that branched-chain amino acids may have important roles in regulating protein, carbohydrate, fat, and amino acid metabolism, and in certain clinical situations, branched-chain amino acids or their ketoanalogues may be used as therapeutic agents.




Fig. 1. Postabsorptive plasma concentrations of leucine (O-O-O), isoleucine (Δ - Δ - Δ), and valine (\bullet - \bullet - \bullet). Before (day 0), during (days 1-6), and after (day 7 and 8), each dietary deprivation in healthy human volunteers [4]. Each value represents the mean \pm SEM of concentration values in six subjects.

Effect on Protein Metabolism

In addition to serving as a substrate for protein synthesis, branched-chain amino acids play a role in protein metabolism. For example, there is stimulation of protein synthesis and inhibition of proteolysis in muscle preparations when branched-chain amino acids are added to the incubation or perfusion medium [7–10]. This effect is unique to branched-chain amino acids since other amino acids do not have a similar effect [8]. In fact, among the branched-chain amino acids, the effect appears to be largely that of leucine [8]. Catabolism of leucine is not required for its effect on protein synthesis, but is required for its effect on protein degradation. For example, prevention of transamination of leucine to α -ketoisocaproate does not block the stimulatory effect on protein synthesis, but does abolish the inhibitory effect on protein degradation [11]. Therefore, α -ketoisocaproate or its metabolites appear to be responsible for the latter effect of leucine.

Although branched-chain amino acids also have an anabolic effect on hepatic protein metabolism, their effect on this tissue does not appear to be unique, since other amino acids have a similar effect [12]. However, when amino acids were individually tested, leucine was the strongest inhibitor of proteolysis in perfused rat liver [13].

In contrast to firm evidence *in vitro*, there is conflicting evidence *in vivo* that leucine stimulates muscle protein synthesis. Some reports have described a stimulatory effect [14] while others have not [15]. Differences in experimental design, such as the methods used to investigate protein synthesis, may have accounted for the varied results. Additional studies are needed to resolve this problem.

Effect on Carbohydrate Metabolism

Leucine in physiological concentration inhibits glucose oxidation by *in vitro* preparations of skeletal muscle and heart of fasted rats [16, 17]. Apparently, this effect is far more pronounced in the muscle preparation of fasted than fed rats. The mechanism of inhibition does not involve alteration in glucose uptake or glycolysis, but seems to include inhibition of pyruvate oxidation [16, 17]. Although all three branched-chain amino acids inhibit muscle oxidation of pyruvate,